Transrectal High Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Factors Influencing the OutcomeGelet A.a,b · Chapelon J.Y.b · Bouvier R.a · Rouvière O.a · Lyonnet D.a · Dubernard J.M.a,b
aUrology Department, Edouard Herriot Hospital, and bINSERM Unit 281, Lyon, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objectives: Efficacy evaluation of high intensity focused ultrasound (HIFU) treatment for localized prostate cancer and identification of the factors affecting the outcome. Patients and Methods: 102 patients with prostate cancer stage T1–T2 and noncandidates for radical prostatectomy have been treated with HIFU (Ablatherm™, EDAP–Technomed). The disease progression (failure) was strictly defined by any positive sample at control biopsies, whatever the prostate–specific antigen (PSA) level, or by 3 consecutive increases in PSA levels in case of negative biopsies. Results: At inclusion, patients’ baseline characteristics were (mean ± standard deviation): age 70.8 (±6.13) years, PSA 8.38 (±4.8) ng/ml, prostate volume 33.3 (±16.71) cm3. The population mean follow–up was 19 months (3–76 months). The overall success rate was 66%. Statistically significant variations of the overall success with a more favorable outcome were observed when (1) the initial PSA level was ≤10 ng/ml (73 vs. 50%, p = 0.02), (2) the Gleason score was ≤6 (81 vs. 46%, p<0.001) and (3) the pretreatment sextant biopsy evidenced 1–4 positive samples (68 vs. 40%, p = 0.01). Conclusion: Results observed after HIFU treatment in localized prostate cancer are now challenging those obtained after radiation therapy. The success rate is influenced by disease–related prognostic factors.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.